IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, today calls upon the global policy leaders and governments to do everything in their power to keep the manufacturing operations and the supply chain of essential medicines operating at full capacity. This will allow our companies to continue to produce much needed critical medicines. While we support the need to protect healthcare workers and to provide hospitals with essential materials, putting unreasonable restrictions on exports of essential medical supplies or medicines will do more harm than good at this time of urgent need.

IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Hanan Sboul, Secretary General of the Jordanian Association of Pharmaceutical Manufacturers, is taking over the position of IGBA Chair for 2020 from Jim Keon, President of the Canadian Generic Pharmaceutical Association and Biosimilars Canada.

The International Generic and Biosimilar Medicines Association (IGBA) welcomes the adoption by the International Council for Harmonization (ICH) of a new topic proposal on Bioequivalence for ImmediateRelease Solid Oral Dosage Forms (M13)i . The ICH Assembly approved the Concept Paper Outline in their November Singapore meeting with the establishment without delay of a new Working Group to initiate work on finalizing the concept paper and business plan for this new topic.